Solesence, Inc. (SLSN) Q1 2026 Earnings Call Transcript

Access earnings results, analyst expectations, report, slides, earnings call, and transcript.

Overview

Despite some positive elements like gross margin improvement and promising order trends, the overall sentiment is negative due to financial losses, shipment delays, and management's vague responses on profitability and operational issues. The company's challenges with OTIF performance, manufacturing inefficiencies, and competitive pressures overshadow the optimistic guidance and strategic initiatives. Without clear short-term actions or metrics, investor confidence is likely to be shaken, leading to a negative stock price reaction.

Key Financial Performance

Revenue $13 million in Q1 2026 compared to $14.6 million in Q1 2025, a decrease due to soft OTIF performance resulting in shipment delays.

Gross Margin Increased by 300 basis points to 26% in Q1 2026, attributed to improved labor efficiency and elimination of product quality-related waste experienced in Q1 2025.

Net Income A loss of $0.8 million in Q1 2026 compared to a net income of $0.08 million in Q1 2025, driven by early-stage investments in operational infrastructure and shipment performance.

Adjusted EBITDA A loss of $107,000 in Q1 2026 compared to a positive $609,000 in Q1 2025, impacted by investments in operational changes and shipment delays.

Shipped and Open Orders Totaled $47 million in Q1 2026, reflecting encouraging booking trends aligned with expectations for a normalized revenue environment.

You have reached the limit. Sign up to access full content

Get started

Operating Highlights

Launch of Chromalum and WHSPR technologies: These proprietary technologies enable the development of SPF-infused hybrid products combining UV protection, skin health benefits, and a joyful user experience. They also expand the company's ability to enter adjacent categories like hair and scalp care.

Expansion of addressable market: The launch of Chromalum and WHSPR technologies allows the company to participate in new product categories and formats, broadening its market reach.

Operational excellence improvements: Gross margin increased by 300 basis points to 26% due to improved labor efficiency and elimination of product quality-related waste. Inventory management and manufacturing efficiencies are being enhanced through the SIOP implementation.

Shift structure and training investments: Updated shift structure and lean manufacturing training were introduced to address extended process changeovers and downtime, aiming to improve labor efficiency and margin profile over time.

Transform and Transcend initiative: A multiyear initiative aimed at transforming operational execution and evolving the company into a strategic supply-side innovation partner. It focuses on operational excellence, leveraging intellectual property, and evolving the service model to capture more value.

Co-marketing activations: Four co-marketing initiatives with brands like Color Science, BloomAX, and Seal have been completed, enhancing product performance and deepening strategic relationships.

You have reached the limit. Sign up to access full content

Get started

Risk or Challenges

Customer Order Cancellations: The company faces risks from potential customer decisions to cancel purchase orders or supply agreements, which could directly impact revenue and operational planning.

Demand and Market Acceptance: Challenges exist in maintaining demand and market acceptance for the company's personal care ingredients, advanced materials, and formulated products, which are critical for revenue generation.

Competitive Pressures: The impact of competitive products and technology poses a risk to the company's market position and ability to sustain growth.

Operational Complexity: The company's transformation and growth have introduced new operating complexities, requiring significant modifications to business processes to capture value and sustain growth.

Supply Chain and Manufacturing Efficiency: Soft OTIF (On-Time, In-Full) performance has led to shipment delays, impacting revenue. Additionally, inefficiencies in manufacturing processes, such as extended process changeovers, have contributed to elevated labor costs.

Economic and External Disruptions: Potential disruptions from public health issues, terrorist activity, and armed conflict could adversely affect commercial activities.

Profitability Pressures: Near-term profitability is under pressure due to investments in operational infrastructure, including new shift structures and lean manufacturing training.

Financial Performance: The company reported a net income loss of $0.8 million and a decline in adjusted EBITDA compared to the previous year, reflecting financial challenges during the early stages of their strategic initiative.

You have reached the limit. Sign up to access full content

Get started

Guidance & Outlook

Transform and Transcend Initiative: A structured multiyear initiative designed to transform operational execution and transcend beyond the traditional CDMO model into a strategic supply-side innovation partner. It focuses on aligning operational performance with technology platforms and positioning the business for long-term sustainable profitability and growth.

Operational Excellence: Efforts include improving inventory management through SIOP implementation, enhancing efficiencies across manufacturing and supply chain processes, and improving procurement and working capital discipline.

Intellectual Property Expansion: Launch of two new proprietary technologies, Chromalum and WHSPR, to develop SPF-infused hybrid products and expand into adjacent categories like hair and scalp care.

Service Model Evolution: Evolving the service model to capture a greater share of the value chain through co-marketing activations and strategic relationships with brand partners.

Revenue Environment: Expectations for a more normalized revenue environment in 2026, with shipped and open orders totaling $47 million.

Gross Profit Margins: Reiterated guidance for a 30% floor for gross profit margins for 2026.

EBITDA Margins: On track to return to double-digit EBITDA margins by the end of 2026, driven by labor efficiency improvements and facility consolidation savings.

Operational Investments: Investments in lean manufacturing structure and training to improve labor efficiency and reduce costs over time.

You have reached the limit. Sign up to access full content

Get started

Shareholder Return Plan

The selected topic was not discussed during the call.

You have reached the limit. Sign up to access full content

Get started

Key Q&A

Q:Are we getting less interest in our product or are sales numbers going down? Do you anticipate ramping up sales for the last three quarters of this year to achieve profitability?

A:The first quarter was impacted by On-Time and In-Full (OTIF) performance due to process changes. The company expects improved results for the rest of the year. The year is seen as one of rationalized performance relative to revenue, not due to less interest in products. There is excitement in new technologies, especially in the SPF-infused beauty space.

Q:Were there stocking and shipment delays that could have created larger revenues for the quarter?

A:Yes, there were delays in receiving raw materials and componentry needed for packaging, particularly at the beginning of the quarter. Improvements were seen as the quarter ended and into Q2. Proper OTIF performance in Q1 would have aligned revenue with prior quarters.

Q:What does the $47 million number represent? Is it a backlog or revenues in progress?

A:The $47 million represents a combination of orders already shipped within the year and open orders due for delivery within the year. It can be considered a backlog by some but is forward-looking. This number is compared to the same time last year to provide guidance.

Q:Review of Unclear Management Responses

A:Management avoided providing specific details about how they plan to achieve profitability or the exact timeline for resolving OTIF issues. Additionally, while they expressed confidence in long-term results and mentioned a strategy document, they did not provide concrete short-term actions or metrics to measure progress.

You have reached the limit. Sign up to access full content

Get started

Earnings Word Cloud

The most frequently occurring keywords in this quarter's earning call

SLSN Transcript

Solesence, Inc. (SLSN) Q1 2026 Earnings Call Transcript

Unknown5-12

Solesence, Inc. (SLSN) Q4 2025 Earnings Call Transcript

Unknown3-31

The earnings call revealed strong financial metrics, including a 10% revenue increase, improved gross margins, and higher net income, which are positive indicators. However, significant risks such as customer cancellations, competitive pressures, and public health issues pose potential challenges. The lack of guidance on 2026 plans and unclear management responses in the Q&A further contribute to uncertainty. Overall, the positive financial performance is offset by the risks and uncertainties, resulting in a neutral sentiment.

Solesence, Inc. (SLSN) Q3 2025 Earnings Call Transcript

Unknown11-11

The earnings call reveals significant issues: declining gross margin and increased operating expenses, leading to a net loss. Management's vague responses in the Q&A, especially on future guidance, amplify uncertainty. Despite some operational improvements and a projected revenue increase, the financial health and lack of clear guidance weigh heavily. The sentiment is negative, reflecting concerns over profitability and strategic clarity.

Solesence, Inc. (SLSN) Q1 2025 Earnings Conference Call Transcript

Positive5-6

The earnings call highlights record revenues, a successful new product launch, and a strong demand pipeline, which are positive indicators. The gross margin decline is attributed to one-time costs, with expectations for improvement. Although there's no shareholder return plan, the company's strategic initiatives, such as securing new patents and improving operations, are promising. The Q&A reveals some concerns over operational issues, but management's corrective measures and strong future revenue expectations suggest a positive outlook, likely resulting in a stock price increase of 2% to 8%.

Frequently Asked Questions

Where does this earnings call transcript come from?

All transcripts are sourced directly from the official live webcast or the company’s official investor relations website. We use the exact words spoken during the call with no paraphrasing of the core discussion.

How soon is the transcript available after the earnings call ends?

Full verbatim transcripts are typically published within 4–12 hours after the call ends. Same-day availability is guaranteed for all S&P 500 and most mid-cap companies.

Is the transcript edited or altered in any way?

No material content is ever changed or summarized in the “Full Transcript” section. We only correct obvious spoken typos (e.g., “um”, “ah”, repeated 10 times”, or clear misspoken ticker symbols) and add speaker names/titles for readability. Every substantive sentence remains 100% as spoken.

Why do some answers appear as “Unclear” or “Inaudible”?

When audio quality is poor or multiple speakers talk over each other, we mark the section instead of guessing. This ensures complete accuracy rather than introducing potential errors.

Who creates the AI Summary and Key Q&A highlights shown above the transcript?

They are generated by a specialized financial-language model trained exclusively on 15+ years of earnings transcripts. The model extracts financial figures, guidance, and tone with 97%+ accuracy and is regularly validated against human analysts. The full raw transcript always remains available for verification.